Ambient (8 - 24 degrees Celsius)
100 uL serum - minimum, 1 mL serum - preferred. Store in fridge
– Not detected
– Positive and pattern
Indirect Immunofluorescence on formalin fixed neutrophils.
ANCA are screened at 1 in 20.
$35.37 (Exclusive of GST)
Anti-neutrophil Cytoplasmic Antibody
Cytoplasmic ANCA (c-ANCA) is typically present in 80-100% of patients with generalised active Wegener’s Granulomatosis (WG), and in a lesser percentage in vasculitic disease within the clinical spectrum of Wegener's Granulomatosis. Antibodies producing the cytoplasmic pattern (c-ANCA) most often react with the azurophilic granule enzyme, proteinase 3 (PR3). However up to 15% of cANCA positive sera have other antigen specificities that at the time of writing have no recognised clinical utility. Antibodies producing the perinuclear pattern (p-ANCA) vary to an even greater extent in their antigen specificity (anti-myeloperoxidase (MPO), anti-elastase, anti-lactoferrin amongst others). As currently only PR3-ANCA and MPO-ANCA have clinical utility it is necessary to run specific assays to define the antibody specificity of all ANCA positive sera. Any serum producing a c-ANCA, p-ANCA or atypical ANCA pattern will be assayed for MPO-ANCA and PR3-ANCA using an ELISA. MPO-ANCA and PR3-ANCA are specific for vasculitic diseases within the clinical spectrum of WG and microscopic polyangiitis although the spectrum of disease associated with these antibodies is expanding.